Characterization of Proteomic Pharmacodynamic Biomarkers of IFNβ‐1a Biologics to Inform Potential Utility in Biosimilar Development

Documenti analoghi

• Evaluating miRNA Sequencing and Integrative Proteomics for Identifying Plasma miRNAs as Potential Pharmacodynamic Biomarkers of IFNβ ‐1a Biologics
  di: Mai Mehanna, et al.
  Pubblicazione: (2025)
• Proteomic Identification of Plasma Biomarkers of Response to IL‐5 Inhibitor Biologics in Healthy Subjects
  di: Lakshmi Manasa S. Chekka, et al.
  Pubblicazione: (2025)
• Interchanging Biosimilars Using Proteomics
  di: Piet H. van der Graaf, et al.
  Pubblicazione: (2025)
• Population Pharmacokinetic and Pharmacodynamic Modeling of Romiplostim Biosimilar GP40141 and Reference Product in Healthy Volunteers to Evaluate Biosimilarity
  di: Igor Makarenko, et al.
  Pubblicazione: (2024)
• Clinical Pharmacology of GP40321 (Insulin Glulisine Biosimilar): Pharmacokinetic and Pharmacodynamic Comparability in a Hyperinsulinemic‐Euglycemic Clamp Procedure
  di: Ekaterina Koksharova, et al.
  Pubblicazione: (2024)